Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

This article first appeared on GuruFocus.

Amgen (NASDAQ:AMGN) has moved to defend Tavneos, a rare disease drug that US regulators are trying to pull from the market, by bringing in the Duke Clinical Research Institute to review the study data behind the medicine. According to a June 1 letter to the FDA posted online Thursday, Duke began reviewing the data in February, giving Amgen another layer of independent analysis as it prepares to push back against the agency's proposed withdrawal.

Warning! GuruFocus has detected 8 Warning Signs with AMGN. Is AMGN fairly valued? Test your thesis with our free DCF calculator.

The FDA has raised concerns that data submitted by Tavneos' prior manufacturer may have been manipulated, while the medical journal that published the original trial results is also investigating the allegations. Amgen plans to submit Duke's new analysis to the FDA by June 29 as part of a broader package supporting the drug. An Amgen spokesperson said the company would review the findings carefully and continue engaging with regulators, investigators, and the healthcare community as appropriate.

For investors, Tavneos could be a drug worth watching because it generates about $500 million in annual sales and came to Amgen through its $3.7 billion acquisition of ChemoCentryx in 2022. The medicine treats ANCA-associated vasculitis, a rare autoimmune disease that can damage small blood vessels and potentially lead to severe kidney and lung issues. However, the FDA has previously said a new independent analysis would not be statistically appropriate and would not redeem the study. Regulators have also flagged possible safety concerns, including eight deaths tied to Tavneos and 20 deaths in Japan after patients took the drug, though the drug's role in those Japan cases remains unclear.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Key Points

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs. Long-term cash flow growth could support future dividend increases.10 stocks we like better than AbbVie ›

AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.

That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.

Following the money

This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.

This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.

The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.

The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.

AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.

The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.

That revenue helps fund research and development, debt reduction, share repurchases, and dividends.

Indeed, oncology helps diversify AbbVie's business.

Diversifying the pipeline

You may remember the company's dependence on Humira.

At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.

That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.

Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.

Image source: Getty Images.

Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.

Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.

And that's why the EHA presentations are relevant.

AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.

Of course, you can't guarantee successful drug development.

Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.

Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.

Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.

AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.

That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.

Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.

And ultimately, it's cash flow that pays dividends.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!

Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 12, 2026.

Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association's 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with elevated LDL-C but no history of heart attack or stroke, the addition of Repatha to existing lipid-lowering therapies reduced the risk of major adverse cardiovascular events by 29% compared to a placebo.

Dr. Jay Bradner, Amgen's EVP of Research and Development, emphasized that early and intensive LDL-C reduction is vital for preventing cardiovascular events in this vulnerable population. The findings held consistent regardless of whether patients were concurrently using SGLT2 inhibitors or GLP-1 receptor agonists, underscoring the necessity of managing multiple risk factors, particularly uncontrolled LDL-C, in individuals living with diabetes.Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now

Beyond the VESALIUS-CV results, Amgen shared real-world evidence identifying significant treatment gaps in current diabetes and obesity care. Studies indicated that low treatment persistence and adherence to GLP-1 therapies often lead to less effective outcomes in clinical practice than those observed in trials. Amgen Inc. (NASDAQ:AMGN) noted that these findings highlight a critical need for new care strategies and treatment approaches that help patients sustain therapy to achieve long-term metabolic health goals.

Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Is AMGN a good stock to buy? We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.'s share was trading at $344.57 as of June 9th. AMGN’s trailing and forward P/E were 23.98 and 15.48 respectively according to Yahoo Finance.Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report

Pressmaster/Shutterstock.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. AMGN is facing a widely acknowledged loss-of-exclusivity (LOE) cliff, with legacy assets such as Enbrel already in decline and Otezla under competitive pressure, yet the market narrative appears to underappreciate the strength and diversification of its replacement engine.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

While consensus frames the upcoming erosion as a structural earnings reset, Amgen’s biosimilars platform has already evolved into a meaningful profit contributor, leveraging decades of biologics manufacturing expertise that creates a durable barrier to entry and positions the company as both incumbent and competitor in the same high-value therapeutic categories. This structural shift meaningfully alters the downside profile of the LOE cycle.

At the same time, the market’s skepticism around Repatha overlooks improving reimbursement dynamics and expanding cardiovascular risk awareness, particularly as GLP-1 therapies elevate the broader cardiometabolic treatment landscape, indirectly reinforcing demand for LDL-lowering therapies with proven outcomes. TEZSPIRE adds another underappreciated growth vector, with severe asthma remaining underpenetrated by biologics and Amgen’s global commercial infrastructure enabling faster adoption than typical emerging peers.

Although the Horizon acquisition has elevated leverage, Amgen’s robust free cash flow generation remains sufficient to comfortably service debt while still funding innovation and shareholder returns. Management’s mid-single-digit revenue growth trajectory through the decade appears conservative relative to pipeline optionality, suggesting embedded upside to consensus expectations.

At current valuation levels, Amgen offers compelling risk-reward profile, combining resilient cash flows, pipeline optionality beyond LOE headwinds, and a biosimilars franchise that monetizes rather than competes against biologic erosion, creating setup where sentiment lags fundamentals and earnings power is being materially underappreciated.

Story Continues

Previously, we covered a bullish thesis on Amgen Inc. (AMGN) by Magnus Ofstad in May 2025, which highlighted strong pipeline assets, biosimilars strength, and resilient earnings despite LOE pressures. AMGN's stock price has appreciated by approximately 22.52% since our coverage. Variant_Invest shares a similar view but emphasizes biosimilar-driven downside protection and cash flow durability over pipeline-led upside.

Amgen Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 65 hedge fund portfolios held AMGN at the end of the first quarter which was 70 in the previous quarter. While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.

As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.

Eli Lilly Hovers Around $1 Trillion Valuation

Eli Lilly LLY shares hit a $1 trillion market value, closing at its first record high since November. The stock has surged more than 25% since the March 30 market low and gained over 400% in the past five years, making Eli Lilly one of Wall Street’s biggest beneficiaries of the obesity-drug boom, per Yahoo Finance. Shares surged about 14% over the past one month (as of June 4, 2026).

Reta Fuels Investor Optimism

Much of the recent excitement centers on retatrutide, or “Reta,” Eli Lilly’s experimental next-generation obesity treatment.

Unlike approved drugs such as Zepbound and Mounjaro, which target two hormone pathways, Reta targets three pathways tied to appetite control, blood sugar regulation and energy use.

In the Phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of participants lost at least 30% of their body weight, results often associated with bariatric surgery, per the same Yahoo Finance article.

GLP-1 Market Expands Beyond Obesity

Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment.

Alongside Eli Lilly, Novo Nordisk NVO, Amgen AMGN and Viking Therapeutics VKTX remain key players in the obesity-drug race. Meanwhile, Indian pharma major Lupin bets big on India’s GLP-1 market.

The trend is also affecting industries outside healthcare, including packaged food, alcohol, restaurant and retail stocks, as investors assess how appetite-suppressing drugs may reshape consumer behavior.

Deloitte Warns of a GLP-1 “Bubble”

A new report from Deloitte suggests soaring demand for obesity and diabetes drugs may be creating a “bubble effect” within the pharmaceutical industry, as quoted on CNBC.

Story Continues

Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage pipeline sales, surpassing oncology for the first time in 16 years.

According to Deloitte, GLP-1 and obesity drugs now represent about 38% of projected commercial inflows from the 2025 late-stage pipeline. Excluding these drugs, the industry’s R&D return falls sharply to 2.9%.

The report also highlighted concentration risk, noting that only 9% of blockbuster late-stage therapies is expected to generate nearly 70% of total risk-adjusted peak sales.

AI and Health Tech Join the GLP-1 Boom

The obesity-drug trend is also driving growth in health technology. Health-tech startup Signos recently raised $20 million in funding and expanded its partnership with Dexcom, per a CNBC article.

Signos uses AI-powered glucose monitoring technology alongside Dexcom’s continuous glucose monitors to help users manage weight through personalized recommendations tied to food, sleep, stress and lifestyle habits.

ETFs to Play

Roundhill GLP-1 and Weight Loss ETF OZEM, Tema Heart & Health ETF HRTS and Amplify Weight Loss Drug & Treatment ETF THNR are some of the ETFs that should be closely tracked in light of the above-mentioned scenario.

LLY-heavy ETFs like the iShares U.S. Pharmaceuticals ETF IHE, Harbor Health Care ETF MEDI and VanEck Pharmaceutical ETF PPH should also benefit from this trend.

NVO-heavy ETFs such as the Simplify Health Care ETF PINK and PPH are also in focus. Meanwhile, Amgen-heavy ETFs like the VanEck Biotech ETF BBH and iShares Biotechnology ETF IBB should not be overlooked amid this euphoria.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

iShares Biotechnology ETF (IBB): ETF Research Reports

Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report

iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports

VanEck Pharmaceutical ETF (PPH): ETF Research Reports

VanEck Biotech ETF (BBH): ETF Research Reports

Simplify Health Care ETF (PINK): ETF Research Reports

Tema Heart & Health ETF (HRTS): ETF Research Reports

Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports

Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Amgen AMGN is one of the several drug makers racing to develop an innovative weight-loss drug and take a share of the booming weight loss drug market. The global obesity drug market is projected to grow dramatically, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates.

Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing. This key feature differentiates it from Eli Lilly’s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound (tirzepatide) and Wegovy (semaglutide), respectively, which are weekly injections. A monthly therapy like MariTide may help reduce treatment burden for patients and improve persistence on treatment over time.

Amgen is evaluating MariTide in type II diabetes, obesity and obesity-related conditions as part of its comprehensive MARITIME phase III program. Amgen has nine global phase III studies underway with MariTide in obesity and other obesity-related conditions like obstructive sleep apnea, cardiovascular disease and heart failure. Three phase III studies of MariTide in type II diabetes will be initiated in 2026.

In clinical studies, it has shown predictable and sustained weight loss and a clinically meaningful impact on cardiometabolic parameters.

In phase II studies, MariTide resulted in up to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau in people who were obese or overweight but without type II diabetes. In patients with type II diabetes who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks.

An interesting study is a new phase III switch study that will assess patients transitioning from weekly tirzepatide or semaglutide therapy to MariTide administered once every eight weeks or once every 12 weeks. In other words, the study will evaluate switching from Zepbound and Wegovy injections given 52 times a year to a medicine that can be injected 4 or 6 times a year.

MariTide is by far Amgen's most important obesity asset. However, Amgen’s obesity pipeline also includes earlier-stage oral and injectable candidates like AMG 513 and AMG 786.

Can AMGN Take Share from LLY and NVO in the Obesity Space?

MariTide is a closely watched drug in the obesity market. However, with MariTide, Amgen is entering a market that is heavily dominated by Lilly and Novo Nordisk. LLY and NVO already have a massive first-mover advantage in the obesity space and enjoy strong brand recognition.

Story Continues

Moreover, to maintain their prowess in the lucrative obesity market, both Novo Nordisk and Lilly are developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates.

Lilly's next-generation candidate, retatrutide, has demonstrated approximately 28% weight loss in late-stage studies, significantly above MariTide's approximately 20%.

This will make it difficult for Amgen to capture rapid market share on a weight-loss efficacy basis, even with a differentiated product like MariTide. However, from another perspective, the obesity market is huge and can support multiple players, and even a modest market share could translate into billions of dollars in annual revenues. MariTide’s less frequent dosing is its biggest competitive advantage, and if successfully developed and launched, MariTide could become the preferred option for patients who value convenience and durable weight maintenance.

Competition Heating Up in the Obesity Space

While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics and Viking Therapeutics are also developing oral GLP-1 drugs for treating obesity.

Others, such as Roche, Merck, AbbVie, and, more recently, Pfizer PFE, have strengthened their obesity pipelines through licensing deals and acquisitions involving smaller biotechs. Pfizer has strengthened its obesity presence with last year’s licensing of YP05002 from YaoPharma and the acquisition of Metsera. AbbVie entered the obesity field by licensing GUB014295 from Gubra. Roche strengthened its obesity presence through the acquisition of Carmot Therapeutics and its obesity assets, such as CT-388, as well as the exclusive collaboration with Zealand Pharma.

AMGN’s Price Performance, Valuation and Estimates

Amgen’s stock has risen 5.3% so far this year compared with an increase of 4.0% for the industry.Zacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.05 forward earnings, which is lower than 17.59 for the industry. The stock is also trading above its five-year mean of 13.81.Zacks Investment Research

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for earnings has declined from $22.29 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.43 to $23.70 per share over the same timeframe.Zacks Investment Research

Image Source: Zacks Investment Research

Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Interessiert an Amgen Inc.? Hier sind fünf Aktien, die wir besser finden. Amgens starke ersten Quartalsergebnisse unterstützen die Idee, dass 2026 ein "Springboard-Jahr" sein könnte, mit einem Umsatzplus von 6% und EPS-Plus von 5%, da Wachstumsprodukte Druck durch Patente und Exklusivitäten auf ältere Medikamente ausgleichen. Die Firma betonte mehrere wichtige Wachstumstreiber – einschließlich Repatha, EVENITY, TEZSPIRE, Onkologie, seltene Krankheiten und Biosimilare – die zusammen etwa 70% der ersten Quartalsproduktverkäufe ausmachten und im Vergleich zum Vorjahr um 24% stiegen. Amgen verlässt sich auch auf sein Pipeline-Portfolio, insbesondere MariTide für Adipositas und Diabetes sowie spätstadiumsprogramme wie olpasiran und xaluritamig, während sie weiterhin UPLIZNA und andere seltene Krankheiten ausbauen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren mögen fragen, ob der Aktienkurs von Amgen noch Wert bietet oder wenn die meisten Chancen bereits im Preis reflektiert sind. Der letzte Schlussstand des Aktienkurses lag bei US$345,73, mit Renditen von 5,3% über 7 Tagen, 4,2% über 30 Tagen, 5,5% bis zum Jahresende, 21,4% über ein Jahr, 70,8% über drei Jahre und 68,7% über fünf Jahre. Die jüngste Aufmerksamkeit auf Amgen hat sich auf seine Position in großen Kapitalbiotechnologie konzentriert und wie Marktteilnehmer die Balance zwischen seinen Wachstumspotenzialen und Risikoprofil bewerten. Dieser Kontext hilft, warum der Aktienkurs eng beobachtet wird, während Investoren neu bewerten, wo sie eine faire Wertigkeit sehen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Antag Therapeutics

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Copenhagen, Denmark, 09 June2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the election of Keith Leonard as Chairman of its Board of Directors.

Keith is a highly experienced global biopharmaceutical executive with 30 years of industry experience leading companies and driving commercial strategies. Throughout his career, Keith has held many leadership positions including Chairman and CEO of Unity Biotechnology, and co-founder, President and CEO of Kythera Biopharmaceuticals, from its founding in 2005 through its acquisition by Allergan plc in 2015.

Prior to Kythera, Keith spent 13 years at Amgen, serving as Senior Vice President and General Manager of Amgen Europe, where he oversaw commercial operations across 28 countries. During his tenure at Amgen, he ran the company’s manufacturing operations in Europe, established Amgen’s presence in inflammation, served as head of information management, and held leadership roles in sales and marketing, engineering, operations, and finance. Keith is currently Chairman of Arcutis Biotherapeutics and sits on the board of Intuitive Surgical.

Keith began his career as an officer in the Civil Engineer Corps of the U.S. Navy. He earned a Master of Business Administration from the Anderson School of Management at the University of California, Los Angeles, holds a Master of Science in mechanical engineering from the University of California, Berkeley, a Bachelor of Arts in history from the University of Maryland, College Park, and a Bachelor of Science in engineering from the University of California, Los Angeles.

“Keith’s election comes at a pivotal time for Antag,” saidPhilip Just Larsen, Chief Executive Officer of Antag Therapeutics. “His deep expertise in leading companies and providing strategic road maps for first-in-class therapies, will be instrumental as we advance AT7687, our Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist into Phase 2 trials.”

Keith Leonard, Chairmanof Antagsaid: “It is an exciting time to be joining Antag in the next chapter of the company’s journey as it prepares to initiate the Phase 2a trial of AT7687. AT7687 is strongly positioned to support next generation treatment paradigms for obesity and cardiometabolic disease. The progress this team has made is truly impressive, and I look forward to contributing to the next phase of growth.”

-ENDS-

About Antag Therapeutics

Antag Therapeutics is a biotechnology company redefining obesity treatment with GIPR antagonism. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option, that goes beyond weight loss to deliver long-term sustained health, without having to compromise on tolerability.

Story Continues

Based on decades of research by GLP-1 pioneer Professor Jens Juul Holst, Antag’s lead molecule, AT7687, is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction. In pre-clinical studies, AT7687 exhibits an excellent tolerability profile, with no need for titration, and improvements across a range of biomarkers related to better cardiovascular outcomes, healthier body composition.

Moreover, AT7687 is a peptide specifically engineered and selected for its straightforward and versatile formulation properties, uniquely positioning Antag to develop AT7687 as monotherapy or as co-formulation with other obesity therapies.

This mechanistically distinct approach suggests a paradigm shift in the treatment of obesity, enabling a new kind of treatment – designed to support more personal, adaptable care – delivering healthier, long-term outcomes for all people with overweight or obesity. The AT7687 Phase 1 clinical trial has been successfully completed, and the Phase 2a study is expected to start in mid-2026.

Antag Therapeutics has raised €80 million in a Series A financing led by Versant Ventures with participation from Novo Holdings, SR One, Dawn Biopharma, Pictet, Longview Ventures, and the Export and Investment Fund of Denmark (EIFO).

Learn more at www.antagtx.com.

Contacts

Antag Therapeutics

Philip Just Larsen

Chief Executive Officer, Antag Therapeutics

Email: pjl@antagtx.com

Antag TherapeuticsMedia Contacts

ICR Healthcare

Amber Fennell, Angela Gray, Evi Useh

Email: antagtx@icrhealthcare.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating

On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed during its first-quarter earnings report that an IRS audit covering the 2016-2018 period had escalated into a formal dispute. Amgen also received a notice of proposed adjustment indicating that the IRS is seeking changes consistent with prior cases, the analyst noted in a research report.

Earlier, on May 14, Piper Sandler reduced its price goal on Amgen to $427 from $432. It maintained an Overweight rating on the shares. From a broader perspective, the firm still sees potential for revenue growth above consensus expectations in both 2026 and 2027. That outlook is driven less by the company’s established commercial products and more by continued momentum in its rare disease business, particularly Uplizna. Piper Sandler also views Tepezza as a potentially stronger growth driver following encouraging Phase III results for its subcutaneous formulation.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and delivers medicines aimed at treating some of the most challenging diseases. The company focuses on areas with significant unmet medical needs and uses its scientific expertise to develop treatments designed to improve patients’ lives.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Oversold Dividend Growth Stocks to Buy and Billionaire Ken Fisher’s Top 11 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

View Comments